Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of “Moderate Buy” by Brokerages

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has earned an average recommendation of “Moderate Buy” from the eight analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $52.3333.

KNSA has been the topic of a number of research analyst reports. The Goldman Sachs Group increased their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Finally, Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA stock opened at $45.39 on Thursday. The stock has a market capitalization of $3.44 billion, a price-to-earnings ratio of 100.87 and a beta of 0.06. Kiniksa Pharmaceuticals International has a one year low of $18.25 and a one year high of $46.65. The company’s 50-day simple moving average is $42.47 and its 200-day simple moving average is $39.21.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 2,690 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $45.00, for a total value of $121,050.00. Following the completion of the transaction, the director directly owned 12,546 shares in the company, valued at $564,570. The trade was a 17.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Eben Tessari sold 12,048 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.56, for a total value of $500,714.88. Following the completion of the sale, the chief operating officer directly owned 16,666 shares in the company, valued at approximately $692,638.96. This trade represents a 41.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 123,823 shares of company stock worth $5,244,967 over the last quarter. 53.48% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently modified their holdings of KNSA. Amundi bought a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth about $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Kiniksa Pharmaceuticals International by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after purchasing an additional 1,002 shares during the period. Millennium Management LLC boosted its stake in Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after purchasing an additional 67,452 shares during the period. Nordea Investment Management AB grew its position in Kiniksa Pharmaceuticals International by 1.6% in the 2nd quarter. Nordea Investment Management AB now owns 130,160 shares of the company’s stock worth $3,582,000 after purchasing an additional 2,110 shares during the last quarter. Finally, Cannon Global Investment Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter valued at approximately $479,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.